These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


210 related items for PubMed ID: 28239818

  • 1. Identification of miR-146b-5p in tissues as a novel biomarker for prognosis of gallbladder carcinoma.
    Lv YP, Shi W, Liu HX, Kong XJ, Dai DL.
    Eur Rev Med Pharmacol Sci; 2017 Feb; 21(3):518-522. PubMed ID: 28239818
    [Abstract] [Full Text] [Related]

  • 2. MicroRNA-146b-5p inhibits the growth of gallbladder carcinoma by targeting epidermal growth factor receptor.
    Cai J, Xu L, Cai Z, Wang J, Zhou B, Hu H.
    Mol Med Rep; 2015 Jul; 12(1):1549-55. PubMed ID: 25760482
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Decreased expression of hsa‑miR‑372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1.
    Zhou N, Cheng W, Peng C, Liu Y, Jiang B.
    Mol Med Rep; 2017 Nov; 16(5):7848-7854. PubMed ID: 28944858
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of microRNAs associated with the survival of patients with gallbladder carcinoma.
    Wang J, Jin Y, Li S, Song Q, Tang P.
    J Int Med Res; 2020 May; 48(5):300060520918061. PubMed ID: 32406793
    [Abstract] [Full Text] [Related]

  • 11. MicroRNA-29c-5p suppresses gallbladder carcinoma progression by directly targeting CPEB4 and inhibiting the MAPK pathway.
    Shu YJ, Bao RF, Jiang L, Wang Z, Wang XA, Zhang F, Liang HB, Li HF, Ye YY, Xiang SS, Weng H, Wu XS, Li ML, Hu YP, Lu W, Zhang YJ, Zhu J, Dong P, Liu YB.
    Cell Death Differ; 2017 Mar; 24(3):445-457. PubMed ID: 28060377
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. LDHA is a direct target of miR-30d-5p and contributes to aggressive progression of gallbladder carcinoma.
    He Y, Chen X, Yu Y, Li J, Hu Q, Xue C, Chen J, Shen S, Luo Y, Ren F, Li C, Bao J, Yan J, Qian G, Ren Z, Sun R, Cui G.
    Mol Carcinog; 2018 Jun; 57(6):772-783. PubMed ID: 29569755
    [Abstract] [Full Text] [Related]

  • 14. MiR-139-5p is associated with poor prognosis and regulates glycolysis by repressing PKM2 in gallbladder carcinoma.
    Chen J, Yu Y, Chen X, He Y, Hu Q, Li H, Han Q, Ren F, Li J, Li C, Bao J, Ren Z, Duan Z, Cui G, Sun R.
    Cell Prolif; 2018 Dec; 51(6):e12510. PubMed ID: 30105813
    [Abstract] [Full Text] [Related]

  • 15. miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinoma.
    Bao RF, Shu YJ, Hu YP, Wang XA, Zhang F, Liang HB, Ye YY, Li HF, Xiang SS, Weng H, Cao Y, Wu XS, Li ML, Wu WG, Zhang YJ, Jiang L, Dong Q, Liu YB.
    Oncotarget; 2016 Apr 19; 7(16):22339-54. PubMed ID: 26968949
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Significance of microRNA-146b-5p in diffuse large B-cell lymphoma and its relationship with risk assessment].
    Cao QW, Li HY, Yao XX, Wang JF.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec 19; 33(12):1010-4. PubMed ID: 23363792
    [Abstract] [Full Text] [Related]

  • 18. Circulating miR-141 as a potential biomarker for diagnosis, prognosis and therapeutic targets in gallbladder cancer.
    Yang G, Lu Z, Meng F, Wan Y, Zhang L, Xu Q, Wang Z.
    Sci Rep; 2022 Jun 16; 12(1):10072. PubMed ID: 35710767
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.